Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yangxinshi vs Trimetazidine in Post-PCI Patients
NCT03809273Phase 4Completed
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Aug 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 4 trial of yangxinshi in coronary artery disease (CAD), sponsored by General Hospital of the Northern Theater Command. Started Aug 2019; status: completed.
02
Drugs
yangxinshi
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03809273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03809273.